(CercleFinance.com) – Novartis presents important data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH trade shows
Novartis will present data from more than 100 trials across its breast cancer and hematology portfolios at the 2023 San Antonio Breast Cancer Symposium (SABCS) and the American Society of Hematology (ASH) Annual Meeting and Exhibition.
The new data will highlight the latest advances in our breast cancer and hematology portfolios and pipelines, such as the Phase III NATALEE trial and the Phase III APPLY-PNH trial.
“We are developing new treatments for a range of cancers and blood disorders and evaluating the potential of our priority drugs in the early stages of disease,” said Jeff Legos, executive vice president and global head of oncology development at Novartis. .
‘Among the new results we will be presenting at SABCS and ASH this year are additional follow-up data on NATALEE’s Kisqali, which adds to the body of evidence for ribociclib in early breast cancer, as well as new 48-week data from the phase III APPLY study. -PNH trial for iptacopan.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
